UAB ORTHO BALTIC

Their core work

Ortho Baltic is a Lithuanian SME specializing in custom-made and mass-customized medical implants, using additive manufacturing and 3D modeling technologies. They develop patient-specific orthopedic solutions, bridging the gap between advanced biomechanical research and commercial implant production. Their work spans the full chain from biomechanical 3D modeling of patient anatomy to the business model design for scalable implant customization.

What they specialise in

How they've shifted over time

Ortho Baltic followed a textbook SME Instrument trajectory: starting in 2016 with a feasibility study on the business model for mass-customized implants (Phase 1), then scaling up through INOVER21 in 2017-2019 (Phase 2, their largest project at EUR 1.59M). By 2019, they expanded into biomechanical 3D modeling research and responsible innovation in additive manufacturing, signaling a deepening of their technical capabilities beyond pure product development.

Moving from commercial scale-up of custom implants toward deeper R&D in biomechanical modeling and additive manufacturing — expect them to seek projects combining clinical 3D modeling with manufacturing innovation.

How they like to work

Ortho Baltic strongly prefers to lead: they coordinated 3 of their 4 projects, indicating confidence in project management and a clear internal vision. With 15 unique partners across 11 countries, they build broad European consortia rather than relying on a fixed circle. Their single participant role in I AM RRI (a responsible innovation project) suggests willingness to join complementary initiatives outside their core when the topic aligns with their manufacturing interests.

Broad European network spanning 15 partners across 11 countries, impressive for a small company with only 4 projects. No obvious geographic concentration — they appear to select partners based on expertise rather than proximity.

What sets them apart

Ortho Baltic is one of few European SMEs that has successfully completed both Phase 1 and Phase 2 of the SME Instrument for medical implant customization, demonstrating proven commercial viability. Their combination of manufacturing capability, biomechanical modeling expertise, and business model innovation makes them a rare partner who understands both the clinical and commercial sides of personalized medical devices. For consortium builders in medtech or additive manufacturing, they bring real production experience — not just research.

Highlights from their portfolio

• INOVER21
  Their flagship Phase 2 SME Instrument project (EUR 1.59M) — represents the commercial scale-up of their core mass-customized implant technology.
• I AM RRI
  Their only project as participant, focused on responsible innovation in additive manufacturing value chains — shows engagement with broader ethical and societal dimensions of their technology.
• BioMech-3D
  MSCA-funded researcher recruitment signals strategic investment in deepening their biomechanical 3D modeling R&D capacity.